|
DOSAGE
|
Post-Op Inflammation (Cataract): 1 gtt qD 24hrs prior to surgery, qDay day of, then qDay x 2 weeks post-op
|
|
INDICATIONS
|
PROLENSA (bromfenac ophthalmic solution) 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
|
|
MECHANISM OF ACTION
|
Prodrug of amfenac | COX inhibitor NSAID
|
|
MICROBIOLOGY
|
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
|
|
CONTRAINDICATIONS & WARNINGS
|
Sulfite Allergic Reactions, Slow or Delayed Healing, Increased Bleeding Time, Keratitis and Corneal Reactions and Potential for Cross-Sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
|
|
Hypersensitivity to any of the ingredients in the formulation. Possible cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory agents.
|
|
PEDIATRIC USE
|
Safety and efficacy in pediatric patients below the age of 18 years have not been established.
|
|
PREGNANCY
|
Category C, Category D in 3rd trimester There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of PROLENSA ophthalmic solution during late pregnancy should be avoided.
|
|
NOTE
|
Typically used instead of pressure patch and cycloplegia to control pain of corneal abrasion.
|
|
All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Remove Contact lens prior to use
|
